HRP20240453T1 - (+)-azasetron za uporabu u liječenju poremećaja uha - Google Patents

(+)-azasetron za uporabu u liječenju poremećaja uha Download PDF

Info

Publication number
HRP20240453T1
HRP20240453T1 HRP20240453TT HRP20240453T HRP20240453T1 HR P20240453 T1 HRP20240453 T1 HR P20240453T1 HR P20240453T T HRP20240453T T HR P20240453TT HR P20240453 T HRP20240453 T HR P20240453T HR P20240453 T1 HRP20240453 T1 HR P20240453T1
Authority
HR
Croatia
Prior art keywords
preparation
use according
hearing loss
ear
azazetrone
Prior art date
Application number
HRP20240453TT
Other languages
English (en)
Croatian (hr)
Inventor
Jonas DYHRFJELD-JOHNSEN
Original Assignee
Sensorion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sensorion filed Critical Sensorion
Priority claimed from PCT/EP2017/059058 external-priority patent/WO2017178645A1/en
Publication of HRP20240453T1 publication Critical patent/HRP20240453T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20240453TT 2016-04-14 2017-04-14 (+)-azasetron za uporabu u liječenju poremećaja uha HRP20240453T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662322690P 2016-04-14 2016-04-14
EP16180192 2016-07-19
PCT/EP2017/059058 WO2017178645A1 (en) 2016-04-14 2017-04-14 (+)-azasetron for use in the treatment of ear disorders
EP17717441.4A EP3442537B1 (en) 2016-04-14 2017-04-14 (+)-azasetron for use in the treatment of ear disorders

Publications (1)

Publication Number Publication Date
HRP20240453T1 true HRP20240453T1 (hr) 2024-06-21

Family

ID=65588799

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240453TT HRP20240453T1 (hr) 2016-04-14 2017-04-14 (+)-azasetron za uporabu u liječenju poremećaja uha

Country Status (18)

Country Link
US (2) US11612605B2 (https=)
EP (1) EP4335508A3 (https=)
JP (1) JP7158723B2 (https=)
CN (1) CN109310698B (https=)
AU (1) AU2023202897B2 (https=)
CL (1) CL2018002930A1 (https=)
DK (1) DK3442537T3 (https=)
ES (1) ES2975016T3 (https=)
FI (1) FI3442537T3 (https=)
HR (1) HRP20240453T1 (https=)
HU (1) HUE066000T2 (https=)
IL (1) IL262305B (https=)
MX (1) MX384045B (https=)
NZ (1) NZ747201A (https=)
PL (1) PL3442537T3 (https=)
RS (1) RS65379B1 (https=)
SI (1) SI3442537T1 (https=)
ZA (1) ZA201806894B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847489B (zh) * 2015-05-18 2021-09-17 森索睿翁公司 用于治疗听力损失的司琼类钙调神经磷酸酶抑制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
CA1304082C (en) 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB0009914D0 (en) 2000-04-20 2000-06-07 Metris Therapeutics Limited Device
GB0104554D0 (en) 2001-02-23 2001-04-11 Glaxo Group Ltd New uses
US20030044356A1 (en) 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
WO2003071986A2 (en) 2002-02-22 2003-09-04 Control Delivery Systems, Inc. Method for treating otic disorders
GB0213869D0 (en) 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
JP2006516977A (ja) 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ,インコーポレイテッド 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US20040204466A1 (en) 2003-04-14 2004-10-14 Orchid Chemicals And Pharmaceuticals Ltd. Treatment of bronchial asthma using 5-HT3 receptor antagonists
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
AU2009271129B2 (en) * 2008-07-14 2013-10-10 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
DK2432467T3 (en) * 2009-05-20 2018-04-16 Inst Nat Sante Rech Med SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS FOR USE IN TREATMENT OF VESTIBULAR DAMAGE LESSONS
ES2432618T3 (es) 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
CN101786963B (zh) 2010-03-03 2013-05-08 山东众诚药业股份有限公司 阿扎司琼中间体的合成方法
WO2013124416A1 (en) 2012-02-23 2013-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
EP2872128B1 (en) 2012-07-16 2020-02-19 Cornell University Nicotinamide riboside to treat hearing loss
BR112016002205A2 (pt) * 2013-07-31 2017-08-01 Bluepharma Ind Farmaceutica S A filmes orodispersíveis
CN104557906A (zh) 2015-01-21 2015-04-29 扬子江药业集团四川海蓉药业有限公司 一种盐酸阿扎司琼的制备方法
CN107847489B (zh) 2015-05-18 2021-09-17 森索睿翁公司 用于治疗听力损失的司琼类钙调神经磷酸酶抑制剂

Also Published As

Publication number Publication date
JP7158723B2 (ja) 2022-10-24
FI3442537T3 (fi) 2024-04-04
EP4335508A3 (en) 2024-07-10
IL262305B (en) 2022-03-01
PL3442537T3 (pl) 2024-07-15
AU2023202897B2 (en) 2025-01-30
US20190083503A1 (en) 2019-03-21
DK3442537T3 (da) 2024-03-25
SI3442537T1 (sl) 2024-05-31
ES2975016T3 (es) 2024-07-02
MX384045B (es) 2025-03-14
RS65379B1 (sr) 2024-04-30
US20230226071A1 (en) 2023-07-20
NZ747201A (en) 2023-02-24
CL2018002930A1 (es) 2019-02-15
AU2023202897A1 (en) 2023-05-25
IL262305A (en) 2018-11-29
EP4335508A2 (en) 2024-03-13
CN109310698B (zh) 2021-12-24
ZA201806894B (en) 2023-03-29
US11612605B2 (en) 2023-03-28
JP2019513780A (ja) 2019-05-30
HUE066000T2 (hu) 2024-06-28
MX2018012587A (es) 2019-03-07
CN109310698A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
RU2469726C2 (ru) Композиции с контролируемым высвобождением на основе кортикостероидов для лечения ушных болезней
HRP20200600T1 (hr) Tapentadol za sprječavanje i liječenje depresije i tjeskobe
HRP20160189T1 (hr) Liječenje crohnove bolesti lakvinimodom
AU2015311674B2 (en) Secnidazole for use in the treatment of bacterial vaginosis
CN107847489A (zh) 用于治疗听力损失的司琼类钙调神经磷酸酶抑制剂
RU2019138166A (ru) Средство для профилактики или лечения атрофии головного мозга
RU2016143979A (ru) Схема дозирования модулятора s1p с немедленным высвобождением
JP2019530706A5 (https=)
MA53368A (fr) Formes galéniques pharmaceutiques à libération modifiée à administrer par voie orale
WO2018004576A3 (en) A fast acting orally disintegrating film for administration of local anesthesia
HRP20240453T1 (hr) (+)-azasetron za uporabu u liječenju poremećaja uha
EP3790543A4 (en) COMPOSITIONS AND DOSAGE FORMS FOR ORAL ADMINISTRATION
PH12019500516A1 (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
HRP20211661T1 (hr) Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti
US10434097B1 (en) Methods and compositions for treating hearing disorders
RU2020108631A (ru) Новая вспомогательная терапия для применения в способе лечения рака простаты
HRP20230735T1 (hr) Betahistin, ili njegova farmaceutski prihvatljiva sol, i inhibitor monoamin oksidaze, za uporabu u liječenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta
RU2011113733A (ru) Производные 1-амино-алкилциклогексана для лечения когнитивного нарушения при шуме в ушах
JP2019513780A5 (https=)
FI3137094T3 (fi) Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen
TH1801006398A (th) (+)-อะซาชีตรอนสำหรับการใช้ในการรักษาความผิดปกติของหู
MX2022007304A (es) Uso de lemborexant para tratamiento del insomnio.
ES2779724T3 (es) Prevención y/o agente terapéutico para la fibromialgia
WO2020013776A3 (en) Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation
WO2020044070A1 (es) Combinación farmacéutica sinérgica que comprende tramadol clorhidrato y pregabalina, y su uso para el tratamiento del dolor neuropático